☆ 4.7 Article

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

BLOOD (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

Ashutosh D. Wechalekar et al.

Summary: This guideline recommends non-transplant chemotherapy treatment for AL amyloidosis patients, based on clinical presentation and patient tolerance. Targeted therapy evaluation and treatment methods for amyloid fibrils are urgently needed.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

Add to Collection

Article Oncology

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Eli Muchtar et al.

Summary: This study validates the use of graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide as indicators. The results show that deeper cardiac response is significantly associated with better survival, and the four-level response performs better than the two-level response in assessing cardiac improvement. Early diagnosis plays an important role in achieving deep cardiac responses.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines

Vaishali Sanchorawala et al.

Summary: These guidelines comprehensively assess the eligibility criteria and strategies for stem cell transplantation treatment in AL amyloidosis patients, including stem cell collection, drug therapy, and supportive care, aiming to improve survival rates and reduce complications for patients.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)

Add to Collection

Article Hematology

How I treat AL amyloidosis

Giovanni Palladini et al.

Summary: The treatment of AL amyloidosis is a challenge for hematologists, but early diagnosis and personalized therapy can improve patient outcomes.

BLOOD (2022)

Add to Collection

Article Hematology

Prognostic restaging after treatment initiation in patients with AL amyloidosis

Nadine Abdallah et al.

Summary: The study found that the currently used staging systems can be used for restaging at 3 and 6 months after treatment initiation, and migration to a higher stage predicts poor prognosis.

BLOOD ADVANCES (2021)

Add to Collection

Article Medicine, General & Internal

Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update

Eli Muchtar et al.

Summary: AL amyloidosis is a clonal plasma cell disorder that can lead to organ failure. Early recognition, anti-plasma cell therapy, and supportive care are important for improving patient survival.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

Andrew Staron et al.

Summary: In recent decades, there have been significant advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis, leading to improved outcomes and decreased early mortality. However, wide survival gaps still exist among different patient subgroups, with most deaths attributed to disease-related factors such as cardiac failure and sudden unexpected death. AL amyloidosis-unrelated mortality has increased over time and with longer-term survival, highlighting the changing landscape of care standards and the overall optimistic outlook for patients with AL amyloidosis.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Hematology

Prognosis and Staging of AL Amyloidosis

Tobias Dittrich et al.

ACTA HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria

Eli Muchtar et al.

LEUKEMIA (2018)

Add to Collection

Review Hematology

Light Chain Amyloidosis

Paolo Milani et al.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2018)

Add to Collection

Article Health Care Sciences & Services

Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis

Tiffany P. Quock et al.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)

Add to Collection

Article Medicine, General & Internal

Systemic immunoglobulin light chain amyloidosis

Giampaolo Merlini et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection

Article Hematology

Epidemiology of AL amyloidosis: a real-world study using US claims data

Tiffany P. Quock et al.

BLOOD ADVANCES (2018)

Add to Collection

Article Biochemistry & Molecular Biology

2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis

Mark Renz et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)

Add to Collection

Article Oncology

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

Morie A. Gertz et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Meeting Abstract Hematology

Improved Survival in AL Amyloidosis: A Population-Based Study on 1,430 Patients Diagnosed in Sweden 1995-2013

Brendan M. Weiss et al.

BLOOD (2016)

Add to Collection

Article Hematology

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

Giovanni Palladini et al.

BLOOD (2014)

Add to Collection

Letter Hematology

Systemic Amyloidosis in England: an epidemiological study

Jennifer H. Pinney et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Evolution and Emergence of Therapeutic Monoclonal Antibodies What Cardiologists Need to Know

Ian N. Foltz et al.

CIRCULATION (2013)

Add to Collection

Article Oncology

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

Shaji Kumar et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils

Jonathan S. Wall et al.

PLOS ONE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.